Disease-Focused Pipeline Aileron Therapeutics is prioritizing orphan pulmonary and fibrosis diseases with its pipeline of innovative medicines, such as LTI-03 for idiopathic pulmonary fibrosis and LTI-01 for loculated pleural effusion. There is a potential sales opportunity in providing these first-in-class treatments for unmet medical needs.
Recent Acquisition Impact The acquisition of Lung Therapeutics has reshaped Aileron's focus and offerings. This strategic move presents a chance for sales development representatives to explore new partnerships and collaborations based on the expanded portfolio and capabilities.
Financial Backing With a recent funding injection of $20 million, Aileron Therapeutics demonstrates financial stability and growth potential. This financial strength can be leveraged by sales teams to negotiate favorable terms and secure long-term partnerships.
Competitive Benchmarking Comparing Aileron to similar companies like Athenex, Blueprint Medicines, and Atara Biotherapeutics reveals opportunities to position the company's offerings uniquely in the market. Understanding competitor strategies can guide sales professionals in crafting compelling value propositions.
Technology Utilization Aileron's tech stack includes Google Cloud, React, and New Relic, showcasing a commitment to cutting-edge technological solutions. Sales development representatives can highlight the company's advanced technology infrastructure as a competitive advantage when engaging with tech-savvy clients.
201
$50M$100M
585$50M$100M
732$100M$1B
283$50M$100M
168$10M$50M
51$10M$50MAileron Therapeutics uses 8 technology products and services including Typekit, Google Cloud, React, and more. Explore Aileron Therapeutics's tech stack below.
| Aileron Therapeutics Email Formats | Percentage |
| FLast@aileronrx.com | 48% |
| FirstL@aileronrx.com | 2% |
| FLast@aileronrx.com | 48% |
| FirstL@aileronrx.com | 2% |
Biotechnology ResearchMassachusetts, United States11-50 Employees
Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website.
Company Overview
Media & News
Funding & FinancialsAileron Therapeutics has raised a total of $20M of funding over 12 rounds. Their latest funding round was raised on May 01, 2024 in the amount of $20M.
Funding & FinancialsAileron Therapeutics has raised a total of $20M of funding over 12 rounds. Their latest funding round was raised on May 01, 2024 in the amount of $20M.
1-888-653-2347 
support@leadiq.com